Strategies to reduce side effects of interleukin-2: Evaluation of the antihypotensive agent N(G)-monomethyl-L-arginine

Cancer Journal from Scientific American

Volumn 6, Issue SUPPL. 1, 2000, Pages

  Kilbourn, Robert G ^a,d   Fonseca, Gustavo A ^b   Trissel, Lawrence A ^b   Griffith, Owen W ^c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d Southwest Regional Cancer Center   (United States)

Author keywords

Endothelium derived relaxing factor; Hypotension; Interleukin 2; Nitric oxide

Indexed keywords

INTERLEUKIN 2; N(G) METHYLARGININE; NITRIC OXIDE; CLEMASTINE FUMARATE; DIPHENOXYLATE; DOBUTAMINE; KETOROLAC TROMETAMOL; MISOPROSTOL; PARACETAMOL; PROCHLORPERAZINE; RECOMBINANT INTERLEUKIN 2; VANCOMYCIN; NITRATE;

ADULT; ARTICLE; BLOOD PRESSURE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FEVER; HEART OUTPUT; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; LUNG CAPILLARY PRESSURE; LUNG EDEMA; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; BLOOD TOXICITY; GASTROINTESTINAL SYMPTOM; NEPHRECTOMY; OLIGURIA; SEIZURE; VASODILATATION; DRUG EFFECT; HEMODYNAMICS; IMMUNOLOGY; KIDNEY TUMOR; LYMPHOKINE ACTIVATED KILLER CELL; METABOLISM; MIDDLE AGED;

ADULT; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPOTENSION; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, LYMPHOKINE-ACTIVATED; MALE; MIDDLE AGED; NITRATES; OMEGA-N-METHYLARGININE;

EID: 0033844391     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Dutcher JP, Atkins M, Fisher R et al. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Cancer J Sci Am 1997;3[suppl 1]:S73-S78.
2. Fisher RI, Rosenberg SA, Sznol M et al. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 1997;3[suppl 1]:S70-S72.
3. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13: 688-696.
4. Ognibene F, Rosenberg S, Lotze M et al. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 1988;94: 750-754.
5. Boccoli G, Masciulli R, Ruggeri EM et al. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment. Cancer Res 1990;50:5795-5800.
6. Kilbourn RG, Belloni P. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin. J Natl Cancer Inst 1990;82:772-776.
7. Booke M, Hinder F, McGuire R et al. Nitric oxide synthase inhibition versus norepinephrine in ovine sepsis: effects on regional blood flow. Shock 1996;5:362-370.
8. G-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 1990;172:1132-1138.
9. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990; 87:3629-3632.
10. G-methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogs. J Appl Physiol 1994;76:1130-1137.
11. Ochoa JB, Curti B, Peitzman AB et al. Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes [published erratum appears in J Natl Cancer Inst 1992;84:1291]. J Natl Cancer Inst 1992;84:864-867.
12. Hibbs JB Jr, Westenfelder C, Taintor R et al. Evidence for cytokine-inducible nirric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy [published erratum appears in J Clin Invest 1992;90:295]. J Clin Invest 1992;89:867-877.
13. West WH, Tauer KW, Yannelli JR et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
14. Pockaj BA, Topalian SL, Steinberg SM et al. Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. J Clin Oncol 1993;11:136-147.
15. Corbin JL, Reporter M. N-G-methylated arginines; a convenient preparation of N-G-methylarginine. Anal Biochem 1974;57:310-312.
16. Owen-Schaub L, Abraham S, Hemstreet G. Phenotypic characterization of murine lymphokine-activated killer cells. Cell Immunol 1986;103:272-278.
17. Braman R, Hendrix SA. Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal Chem 1989; 61:2715-2718.
18. G-monomerhyl-L-arginine in human and dog serum using pre-column o-phthaldialdehyde derivatization and high performance liquid chromatography. J Liq Chrom Rel Technol 1997;20:1839-1848.
19. Du Bois J, Trehu E, Meir J et al. Randomized placebo controlled clinical trial of high-dose interleukin-2 (IL-2) in combination with the soluble TNF receptor IgG chimera (TNFR:Fc) [abstract]. Proc Am Soc Clin Oncol 1995;14:258.
20. Margolin K, Atkins M, Sparano J et al. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 dierapy in advanced renal cancer and malignant melanoma. Clin Cancer Res 1997;3:565-572.
21. Thompson JA, Bianco JA, Benyunes MC et al. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res 1994;54:3436-3441.
22. Mier JW, Vachino G, Klempner MS et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 1990;76:1933-1940.
23. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989;86:3375-3378.
24. Kilbourn R, Owen-Schaub L, Grimm L. Neither lymphokine-activated killer cell activity nor tumor necrosis factor (TNF) mediated tumor cell lysis is altered by inhibitors of nitric oxide synthesis [abstract]. Proc Am Soc Clin Oncol 1991;32:251.
25. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
26. Kumar A, Thota V, Dee L et al. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996; 183:949-958.
27. Kilbourn RG, Cromeens DM, Chelly FD et al. NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs. Crit Care Med 1994;22:1835-1840.
28. Klemm P, Thiemermann C, Winklmaier G et al. Effects of nitric oxide synthase inhibition combined with nitric oxide inhalation in a porcine model of endotoxin shock. Br J Pharmacol 1995;114: 363-368.
29. Weitzberg E, Rudehill A, Modin A et al. Effect of combined nitric oxide inhalation and NG-nitro-L-arginine infusion in porcine endotoxin shock. Crit Care Med 1995;23:909-918.
30. Samlowski WE, Yim CY, McGregor JR et al. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice. J Immunother Emphasis Tumor Immunol 1995;18:166-178.
31. Kilbourn RG, Szabo C, Traber DL. Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies. Shock 1997; 7:235-246.